Hester Biosciences Ltd

- There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript. - The management discussed existing loans, especially dollar loans taken by the African subsidiary, resulting in higher finance costs due to currency fluctuations. - The CFO indicated that the recent jump in finance costs is a one-time event and not expected to continue at the same high level, but future finance costs might be slightly higher than earlier quarters. - The focus appears to be on improving profitability and operational efficiency rather than raising new capital. - No direct comments or guidance were provided about raising additional funds through debt or equity in the near term.

- The company is focused on enhancing operational efficiency both in the field and backend, indicating ongoing investments to improve productivity (Page 5). - There is a mention of gearing up to launch new and modified products in Animal Healthcare and Pet Care divisions, which may require capital allocation for product development and marketing (Page 5). - Hester Africa plant has 6 registered vaccines, with 5 more vaccines in the registration process by the end of the financial year, indicating investment in regulatory and market expansion efforts (Page 4). - The harmonization of the vaccine registration process in Africa is expected to enable quicker market entry, suggesting strategic investment to facilitate business growth (Page 4). - No explicit mention of large-scale capex or major capital investments was made in the transcript for the current or near future period. The focus seems more on product launches and operational improvements.

- Focus on improving profitability and bottom line through operational efficiency and product mix rationalization. - Expansion of sales in Africa with expectation of registration of additional products and increased exports. - Launch of upgraded products like line extensions under Protein C in Animal Healthcare and modified Newcastle Disease Vaccine targeting better performance. - Growth in Pet Care division, driven by expansion into Tier 2 and Tier 3 cities. - Recovery expected in exports and poultry industry which had impacted recent sales. - New health products launched (CuRx LA and substitute for iSumovet) to recoup loss due to withdrawal of earlier products. - Continued emphasis on government tenders for vaccines like PPR and GPV contributing to steady sales. - Anticipated increase in vaccine sales through national immunization programs (e.g., Lumpy Skin Disease and CPR vaccine). - Management aims to reach earlier higher EBITDA margins within 2-3 years by gaining traction and efficiency.

- Hester Biosciences aims to improve profitability and return to earlier EBITDA margin levels (~35%) within 2-3 years by enhancing sales efficiency and gaining traction in new segments. - The company expects normalized margins to recover despite investments in pet care and setbacks in Nepal and Africa. - Growth will be driven by expansion in health products, pet care (especially tier 2 and 3 cities), and increased exports, particularly from Africa as more vaccines get registered. - New product launches, including line extensions in Animal Healthcare and Pet Care divisions, are expected to boost sales. - Recovery in exports and poultry industry conditions is anticipated, aiding revenue and margin improvement in H2 FY24. - Currency fluctuation-related finance costs are expected to moderate from current elevated levels, supporting bottom-line improvement. - Overall, management is confident of improving operating profits backed by execution on strategic goals and market expansion.

- The company did not explicitly mention the exact current or expected order book size during the call. - However, they highlighted a few key ongoing and upcoming orders: - Supply of 30 crore doses of CPR vaccine as part of the national immunization program, expected to be completed by October 2024. - Distribution of 3 to 3.5 crore doses of goat pox vaccine for the lumpy skin disease immunization over the next two quarters. - They indicated a strong focus on government tenders, especially for PPR and GPV vaccines, contributing to growth. - There is an ongoing registration process for vaccines in African countries expected to enable prompt marketing and sales. - New health product launches (CuRx LA and iSumovet substitutes) are planned to offset sales loss, implying anticipated new orders in coming quarters.